EDP Sciences logo
Authentification abonné
Rechercher
Menu
Accueil Tous les numéros Volume 36 / Numéro 10 (Octobre 2020) Med Sci (Paris), 36 10 (2020) 900-907 Références
Rétine
Open Access
Numéro
Med Sci (Paris)
Volume 36, Numéro 10, Octobre 2020
Rétine
Page(s) 900 - 907
Section M/S Revues
DOI https://doi.org/10.1051/medsci/2020163
Publié en ligne 7 octobre 2020
  1. De Verdier K, Ulla E, Löfgren S, et al. Children with blindness: major causes, developmental outcomes and implications for habilitation and educational support: a two-decade. Swedish population-based study. Acta Ophthalmol 2018 ; 96 : 295–300. [Google Scholar]
  2. Blencowe H, Lawn JE, Vazquez T, et al. Preterm-associated visual impairment and estimates of retinopathy of prematurity at regional and global levels for 2010. Pediatr Res 2013 ; 74(suppl 1): 35–49. [CrossRef] [PubMed] [Google Scholar]
  3. Chan H, Cougnard-Grégoire A, Korobelnik JF, et al. Screening for retinopathy of prematurity by telemedicine in a tertiary level neonatal intensive care unit in France: review of a six-year period. J Fr Ophtalmol 2018 ; 41 : 926–932. [CrossRef] [PubMed] [Google Scholar]
  4. Holmström G, Tornqvist K, Al-Hawasi A, et al. Increased frequency of retinopathy of prematurity over the last decade and significant regional differences. Acta Ophthalmol 2018 ; 96 : 142–148. [CrossRef] [PubMed] [Google Scholar]
  5. Sapieha P, Joyal JS, Rivera JC, et al. Retinopathy of prematurity: understanding ischemic retinal vasculopathies at an extreme of life. J Clin Invest 2010 ; 120 : 3022–3032. [CrossRef] [PubMed] [Google Scholar]
  6. Beauchamp MH, Sennlaub F, Speranza G, et al. Redox-dependent effects of nitric oxide on microvascular integrity in oxygen-induced retinopathy. Free Radical Bio Med 2004 ; 37 : 1885–1894. [CrossRef] [Google Scholar]
  7. Brooks SE, Gu X, Samuel S, et al. Reduced severity of oxygen-induced retinopathy in eNOS-deficient mice. Invest Ophthalmol Vis Sci 2001 ; 42 : 222–228. [PubMed] [Google Scholar]
  8. Kermorvant-Duchemin E, Sennlaub F, Sirinyan M, et al. Trans-arachidonic acids generated during nitrative stress induce a thrombospondin-1-dependent microvascular degeneration. Nat Med 2005 ; 11 : 1339–1345. [CrossRef] [PubMed] [Google Scholar]
  9. Askie LM, Darlow BA, Davis PG, et al. Effects of targeting lower versus higher arterial oxygen saturations on death or disability in preterm infants. Cochrane Database Syst Rev 2017; 4 : CD011190. [PubMed] [Google Scholar]
  10. Brion LP, Bell EF, Raghuveer TS. Vitamin E supplementation for prevention of morbidity and mortality in preterm infants. Cochrane Database Syst Rev 2003; CD003665. [Google Scholar]
  11. Alon T, Hemo I, Itin A, et al. Vascular endothelial growth factor acts as a survival factor for newly formed retinal vessels and has implications for retinopathy of prematurity. Nat Med 1995 ; 1 : 1024–1028. [CrossRef] [PubMed] [Google Scholar]
  12. Pierce EA, Foley ED, Smith LE. Regulation of vascular endothelial growth factor by oxygen in a model of retinopathy of prematurity. Arch Ophthalmol 1996; 114 : 1219–28 (erratum 1997; 115 : 427). [CrossRef] [PubMed] [Google Scholar]
  13. Shih SC, Ju M, Liu N, et al. Selective stimulation of VEGFR-1 prevents oxygen-induced retinal vascular degeneration in retinopathy of prematurity. J Clin Invest 2003 ; 112 : 50–57. [CrossRef] [PubMed] [Google Scholar]
  14. Chen J, Connor KM, Aderman CM, et al. Erythropoietin deficiency decreases vascular stability in mice. J Clin Invest 2008 ; 118 : 526–533. [PubMed] [Google Scholar]
  15. Fang JL, Sorita A, Carey WA, et al. Interventions to prevent retinopathy of prematurity: a meta-analysis. Pediatrics 2016 ; 137 : e20153387. [PubMed] [Google Scholar]
  16. Hellstrom A, Perruzzi C, Ju M, et al. Low IGF-I suppresses VEGF-survival signaling in retinal endothelial cells: direct correlation with clinical retinopathy of prematurity. Proc Natl Acad Sci USA 2001 ; 98 : 5804–5808. [CrossRef] [Google Scholar]
  17. Vanhaesebrouck S, Daniëls H, Moons L, et al. Oxygen-induced retinopathy in mice: amplification by neonatal IGF-I deficit and attenuation by IGF-I administration. Pediatr Res 2009 ; 65 : 307–310. [CrossRef] [PubMed] [Google Scholar]
  18. Hellstrom A, Engstrom E, Hard AL, et al. Postnatal serum insulin-like growth factor I deficiency is associated with retinopathy of prematurity and other complications of premature birth. Pediatrics 2003 ; 112 : 1016–1020. [PubMed] [Google Scholar]
  19. Hellström A, Hård A-L, Engström E, et al. Early weight gain predicts retinopathy in preterm infants: new, simple, efficient approach to screening. Pediatrics 2009 ; 123 : e638–e645. [PubMed] [Google Scholar]
  20. Stoltz Sjöström E, Lundgren P, Öhlund I, et al. Low energy intake during the first 4 weeks of life increases the risk for severe retinopathy of prematurity in extremely preterm infants. Arch Dis Child Fetal Neonatal Ed 2016; 101 : F108–13. [CrossRef] [PubMed] [Google Scholar]
  21. Ley D, Hallberg B, Hansen-Pupp I, et al. rhIGF-1/rhIGFBP-3 in preterm infants: a phase 2 randomized controlled trial. J Pediatr 2019 ; 206 : 56–65.e8. [CrossRef] [PubMed] [Google Scholar]
  22. Lapillonne A. Eleni dit Trolli S, Kermorvant-Duchemin E. Postnatal docosahexaenoic acid deficiency is an inevitable consequence of current recommendations and practice in preterm infants. Neonatology 2010 ; 98 : 397–403. [CrossRef] [PubMed] [Google Scholar]
  23. Connor KM, SanGiovanni JP, Lofqvist C, et al. Increased dietary intake of omega-3-polyunsaturated fatty acids reduces pathological retinal angiogenesis. Nat Med 2007 ; 13 : 868–873. [CrossRef] [PubMed] [Google Scholar]
  24. Pawlik D, Lauterbach R, Walczak M, et al. Fish-oil fat emulsion supplementation reduces the risk of retinopathy in very low birth weight infants: a prospective, randomized study. J Parenter Enteral Nutr 2014 ; 38 : 711–716. [CrossRef] [Google Scholar]
  25. Mohsen L, Abou-Alam M, El-Dib M, et al. A prospective study on hyperglycemia and retinopathy of prematurity. J Perinatol 2014 ; 34 : 453–457. [CrossRef] [PubMed] [Google Scholar]
  26. Kermorvant-Duchemin E, Pinel AC, Lavalette S, et al. Neonatal hyperglycemia inhibits angiogenesis and induces inflammation and neuronal degeneration in the retina. PLoS One 2013 ; 8 : e79545. [CrossRef] [PubMed] [Google Scholar]
  27. International committee for the classification of retinopathy of prematurity. The international classification of retinopathy of prematurity revisited. Arch Ophthalmol 2005; 123 : 991–9. [CrossRef] [PubMed] [Google Scholar]
  28. Barjol A, Lux AL, Soudée S, et al. Recommandations françaises pour le dépistage de la rétinopathie des prématurés. Paris : Société Française d’Ophtalmologie, 2015. [Google Scholar]
  29. Daniel E, Quinn GE, Hildebrand PL, et al. Validated system for centralized grading of retinopathy of prematurity: telemedicine approaches to evaluating acute-phase retinopathy of prematurity (e-ROP) study. JAMA Ophthalmol 2015 ; 133 : 675–682. [CrossRef] [PubMed] [Google Scholar]
  30. Campbell JP, Ataer-Cansizoglu E, Bolon-Canedo V, et al. Expert diagnosis of plus disease in retinopathy of prematurity from computer-based image analysis. JAMA Ophthalmol 2016 ; 134 : 651–657. [CrossRef] [PubMed] [Google Scholar]
  31. Early treatment for retinopathy of prematurity cooperative group Revised indications for the treatment of retinopathy of prematurity: results of the early treatment for retinopathy of prematurity randomized trial. Arch Ophthalmol 2003 ; 121 : 1684–1694. [CrossRef] [PubMed] [Google Scholar]
  32. Wang SD, Zhang GM, Shenzhen screening for retinopathy of prematurity cooperative group. Laser therapy versus intravitreal injection of anti-VEGF agents in monotherapy of ROP: a meta-analysis. Int J Ophthalmol 2020; 13 : 806–15. [CrossRef] [PubMed] [Google Scholar]
  33. Cryotherapy for retinopathy of prematurity cooperative group Multicenter trial of cryotherapy for retinopathy of prematurity. Preliminary results. Arch Ophthalmol 1988 ; 106 : 471–479. [CrossRef] [Google Scholar]
  34. The early treatment for retinopathy of prematurity cooperative group. Grating visual acuity results in the early treatment for retinopathy of prematurity study. Arch Ophthalmol 2011; 129 : 840–6. [CrossRef] [PubMed] [Google Scholar]
  35. Mintz-Hittner HA, Kennedy KA, Chuang AZ, et al. Efficacy of intravitreal bevacizumab for stage 3+ retinopathy of prematurity. N Engl J Med 2011 ; 364 : 603–615. [Google Scholar]
  36. Han J, Kim SE, Lee SC, et al. Low dose versus conventional dose of intravitreal bevacizumab injection for retinopathy of prematurity: a case series with paired-eye comparison. Acta Ophthalmol 2018 ; 96 : e475–e478. [CrossRef] [PubMed] [Google Scholar]
  37. Stahl A, Lepore D, Fielder A, et al. Ranibizumab versus laser therapy for the treatment of very low birthweight infants with retinopathy of prematurity (Rainbow): an open-label randomised controlled trial. Lancet 2019 ; 394 : 1551–1559. [CrossRef] [PubMed] [Google Scholar]
  38. Lepore D, Quinn GE, Molle F, et al. Intravitreal bevacizumab versus laser treatment in type 1 retinopathy of prematurity: report on fluorescein angiographic findings. Ophthalmology 2014 ; 121 : 2212–2219. [Google Scholar]
  39. Ittiara S, Blair MP, Shapiro MJ, et al. Exudative retinopathy and detachment: a late reactivation of retinopathy of prematurity after intravitreal bevacizumab. J AAPOS 2013 ; 17 : 323–325. [CrossRef] [PubMed] [Google Scholar]
  40. Yonekawa Y, Thomas BJ, Thanos A, et al. The cutting edge of retinopathy of prematurity care: expanding the boundaries of diagnosis and treatment. Retina 2017 ; 37 : 2208–2225. [CrossRef] [PubMed] [Google Scholar]
  41. Alyamaç Sukgen E, Çömez A, Koçluk Y, et al. The process of retinal vascularization after anti-VEGF treatment in retinopathy of prematurity: a comparison study between ranibizumab and bevacizumab. Ophthalmologica 2016; 236 : 139–47. [CrossRef] [PubMed] [Google Scholar]
  42. Novitskaya ES, Dahlmann-Noor AH, Adams GGW, et al. Retinopathy of prematurity treatment in the UK: trends in neonatal anaesthetic support and location of treatment from a national surveillance study. Eur J Pediatr 2020; May 4. doi: 10.1007/s00431-020-03650-3. [Google Scholar]
  43. Wu WC, Lien R, Liao PJ, et al. Serum levels of vascular endothelial growth factor and related factors after intravitreous bevacizumab injection for retinopathy of prematurity. JAMA Ophthalmol 2015 ; 133 : 391–397. [CrossRef] [PubMed] [Google Scholar]
  44. Hoerster R, Muether P, Dahlke C, et al. Serum concentrations of vascular endothelial growth factor in an infant treated with ranibizumab for retinopathy of prematurity. Acta Ophthalmol 2013 ; 91 : e74–e75. [CrossRef] [PubMed] [Google Scholar]
  45. Natarajan G, Shankaran S, Nolen TL, et al. Neurodevelopmental outcomes of preterm infants with retinopathy of prematurity by treatment. Pediatrics 2019 ; 144 : e20183537. [PubMed] [Google Scholar]
  46. Ahmed K, Ali AS, Delwadia N, et al. Neurodevelopmental outcomes following intravitreal bevacizumab with laser versus laser photocoagulation alone for retinopathy of prematurity. Ophthalmic Surg Lasers Imaging Retina 2020; 51 : 220–4. [CrossRef] [PubMed] [Google Scholar]
  47. Sen P, Bhende P, Rishi E, et al. Anatomical and visual outcomes in stage 5 retinopathy of prematurity with microincision vitrectomy surgery. Retina 2020; doi: 10.1097/IAE.0000000000002837. [Google Scholar]
  48. Uner OE, Rao P, Hubbard GB. Reactivation of retinopathy of prematurity in adults and adolescents. Ophthalmol Retina 2020; S2468–6530(20)30056–7. [Google Scholar]
  49. Al-Taie R, Simkin SK, Douçet E, et al. Persistent avascular retina in infants with a history of type 2 retinopathy of prematurity: to treat or not to treat?. J Pediatr Ophthalmol Strabismus 2019 ; 56 : 222–228. [PubMed] [Google Scholar]
  50. Hellgren KM, Tornqvist K, Jakobsson PG, et al. Ophthalmologic outcome of extremely preterm infants at 6.5 years of age: extremely preterm infants in Sweden study (Express). JAMA Ophthalmol 2016; 134 : 555–62. [CrossRef] [PubMed] [Google Scholar]
  51. Chan-Ling T, Gole GA, Quinn GE, et al. Pathophysiology, screening and treatment of ROP: a multi-disciplinary perspective. Prog Retin Eye Res 2018 ; 62 : 77–119. [CrossRef] [PubMed] [Google Scholar]

Les statistiques affichées correspondent au cumul d'une part des vues des résumés de l'article et d'autre part des vues et téléchargements de l'article plein-texte (PDF, Full-HTML, ePub... selon les formats disponibles) sur la platefome Vision4Press.

Les statistiques sont disponibles avec un délai de 48 à 96 heures et sont mises à jour quotidiennement en semaine.

Le chargement des statistiques peut être long.